Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Clark Street Value. This analysis is provided for institutional research purposes only and is not investment advice.
"Clark Street Value struggled in the first half of 2025, returning -3.64% as structural and microcap investments lagged, but continues to heavily position in net-cash biotechs and microcap thrifts primed for buyouts."
The manager's portfolio experienced a -3.64% return during H1 2025, lagging the S&P 500's return of 6.20%. Key active exposures are heavily weighted towards 'busted biotechs' undergoing strategic reviews or liquidations (such as THRD, CRGX, and EPIX) and demutualized regional thrifts (NSTS). Several legacy/underperforming positions (ME, HHH, ACR) and completed merger arbitrage plays (DNB, ELEV, ENZ) were liquidated during the period to raise cash and redeploy into higher-conviction special situations.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: Clark Street Value struggled in the first half of 2025, returning -3.64% as structural and microcap investments lagged, but continues to heavily position in net-cash biotechs and m...
Growth Outlook
Market outlook remains moderate conviction: Clark Street Value struggled in the first half of 2025, returning -3.64% as structural and microcap investments lagged, but continues to heavily position in net-cash biotechs and m...
Risk Appetite
Risk appetite posture is above average conviction: Clark Street Value struggled in the first half of 2025, returning -3.64% as structural and microcap investments lagged, but continues to heavily position in net-cash biotechs and m...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. Clark Street Value struggled in the first half of 2025, returning -3.64% as structural and microcap investments lagged, but continues to heavily position in net-cash biotechs and m...
Forward Guidance
Forward guidance signal: Clark Street Value struggled in the first half of 2025, returning -3.64% as structural and microcap investments lagged, but continues to heavily position in net-cash biotechs and m...
Language Signal
Tone analysis indicates above average conviction language: Clark Street Value struggled in the first half of 2025, returning -3.64% as structural and microcap investments lagged, but continues to heavily position in net-cash biotechs and m...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. Clark Street Value struggled in the first half of 2025, returning -3.64% as structural and microcap investments lagged, but continues to heavily position in net-cash biotechs and m...
Opportunity Density
Opportunity density index indicates high conviction actionable entry points. Clark Street Value struggled in the first half of 2025, returning -3.64% as structural and microcap investments lagged, but continues to heavily position in net-cash biotechs and m...
Time Horizon
Investment time horizon reflects a above average conviction orientation. Clark Street Value struggled in the first half of 2025, returning -3.64% as structural and microcap investments lagged, but continues to heavily position in net-cash biotechs and m...
